KLRK1 and plasma cell myeloma: NKG2D has emerged as a promising target, and its safety has been demonstrated in the treatment of multiple myeloma and myelodysplastic Syndromes/Acute Myeloid Leukemia using NKG2D-based CAR NK cells.